FDA Inspection
Glenmark Pharmaceuticals LimitedGlenmark Pharmaceuticals Limited – FDA Inspection, May 20, 2022
Record Details
This FDA Inspection record concerns Glenmark Pharmaceuticals Limited, with an inspection on May 20, 2022, issued by the Center for Drug Evaluation and Research, covering drugs.
- Inspection Date
- May 20, 2022
- Product Type
- Drugs
View Company Profile
ID · 3db03adb-b93f-4e9a-8ec6-4f05144e5a4f
Inspection Facts
Official Action Indicated (OAI)
Significant objectionable conditions were found and regulatory or administrative action is recommended.
- Inspection number
- 1170118
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
FDA Citations
5- 21 CFR 211.188Prepared for each batch, include complete information
- 21 CFR 211.63Equipment Design, Size and Location
- 21 CFR 211.192Extent of discrepancy, failure investigations
- 21 CFR 211.160(b)Scientifically sound laboratory controls
- 21 CFR 211.100(a)Absence of Written Procedures
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Glenmark Pharmaceuticals Limited
7| Date | Classification | Office | Project area |
|---|---|---|---|
| September 27, 2019 | VAI | Office of Inspections and Investigations | Generic Drug Evaluation |
| March 15, 2019 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| March 31, 2017 | Not classified | Office of Inspections and Investigations | |
| May 30, 2014 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| July 19, 2013 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for Glenmark Pharmaceuticals Limited
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.